
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio Inc has shown a positive financial outlook due to a beneficial settlement with GSK, resulting in an increase in royalty rates for Jemperli sales and a one-time cash infusion of $60 million. This settlement enhances confidence in AnaptysBio's business model, as it signals operational stability while maintaining adequate capital to support ongoing clinical-stage programs. Furthermore, the company's ongoing trials for immune cell modulating antibodies, including significant indications for autoimmune and inflammatory diseases, position AnaptysBio favorably for potential revenue growth and expanded partnership opportunities.
Bears say
AnaptysBio Inc faces significant risks that contribute to a negative outlook on its stock, primarily related to the safety and efficacy of its clinical programs, particularly for its lead candidates, rosnilimab and ANB032. The company is also vulnerable to greater-than-expected competition in the commercial landscape, which could undermine its market position and projected sales for its products, including Jemperli. Furthermore, unresolved legal issues and potential regulatory hurdles present additional uncertainties that could negatively impact investor confidence and the company’s financial performance.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares